Zacks Research Upgrades Novozymes A/S (OTCMKTS:NVZMY) to “Hold”
by Teresa Graham · The Cerbat GemNovozymes A/S (OTCMKTS:NVZMY – Get Free Report) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.
Other research analysts also recently issued reports about the stock. Rothschild & Co Redburn upgraded shares of Novozymes A/S to a “strong-buy” rating in a research note on Friday, March 27th. Kepler Capital Markets upgraded shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy”.
Get Our Latest Analysis on Novozymes A/S
Novozymes A/S Price Performance
NVZMY stock opened at $59.04 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a current ratio of 1.67. Novozymes A/S has a 1 year low of $49.90 and a 1 year high of $75.99. The firm has a market cap of $24.48 billion, a P/E ratio of 39.89, a price-to-earnings-growth ratio of 1.05 and a beta of 0.95. The stock has a 50-day simple moving average of $59.38 and a 200-day simple moving average of $60.43.
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). Novozymes A/S had a return on equity of 6.52% and a net margin of 14.22%.The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.32 billion. On average, equities analysts predict that Novozymes A/S will post 2.43 earnings per share for the current fiscal year.
Novozymes A/S Company Profile
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).